EDN1 and colorectal cancer: Collectively, our in vivo findings provide strong evidence that pharmacological blockade of EDN1 using bosentan enhances the anti-tumor efficacy of oxaliplatin and may represent a promising strategy to overcome oxaliplatin resistance in colorectal cancer.